SCHEMBL2998218

SCHEMBL2998218

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KCNH2 Q12809 1/20 0.37
MAPT P10636 4/20 0.35
USP2 O75604 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 3/20 0.35
TSHR P16473 2/20 0.35
POLB P06746 2/20 0.35
HTT P42858 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
RAB9A P51151 3/20 0.35
EPHX2 P34913 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001160 0.93 DRD2 (0.38) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3009991 0.92 LMNA (0.35) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3007969 0.91 MAPT (0.36) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3013182 0.90 LMNA (0.37) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3004586 0.90 RAB9A (0.40) HTR2AHTR2CMAPTLMNATSHR
SCHEMBL3007230 0.90 SMN1; SMN2 (0.38) MAPTALDH1A1LMNATSHRPOLB
SCHEMBL3013735 0.88 GPR6 (0.39) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3001734 0.88 SMN1; SMN2 (0.40) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3008528 0.87 DRD2 (0.37) DRD2HTR2AHTR2CKCNH2MAPT
SCHEMBL3010517 0.87 TSHR (0.49) MAPTUSP2RECQLHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885HTR2A 752/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.